

# TABLE OF CONTENTS

June 22, 2009

No. 2144

## BUSINESS

- 1 Teijin to Create Its Own Marketing System in Asia
  - Generics, New Competitors Will Have No Major Impact on Bonalon
  - TMX-67 to Be Applied for in Japan within 2009
- 2 Wyeth to Improve RA Patients' Access to Biologics
- 3 Production of Drugs May Be Negatively Affected by Healthcare Reform: YANO Research
- 4 Mediceo Paltac to Invest in Drug Wholesaler in China
- 4 Give Incentives to Those Who Settle Prices Earlier: Mr Bessho
- 5 Ultmarc to Hire More Healthcare Professionals to Provide More Customer-Oriented Services
- 5 **BUSINESS NEWS IN BRIEF**
  - Sanofi Pasteur Receives Order from US Gov't for New Flu Vaccine
  - HSTTC Transfers NIH's Technology to COSMO BIO

## GENERICS

- 6 Top-Four Generic Firms' Business Grows by Leaps and Bounds
- 7 Taiyo Aims at Sales of Over ¥50 Bil. with 227 MRs in FY2009
  - Sales through Wholesalers Increasing
- 8 Pharmacies Should Give List of Generics They Stock to Medical Institutions: Mr Kinoshita
  - Hospitals Should Accept MSs: Mr Eguchi
  - *Hansha's* Combined Sales Total ¥96,879 Mil. in FY2008
- 9 Generics May Be Approved Even if Original Drugs Are Covered by Valid Use Patents
- 9 **GENERICS NEWS IN BRIEF**
  - Mylan Launches 10 New Products
  - NCVC Shows Highest Use of Generics

## REGULATORY

- 10 NHI Price Listing Recommended for Approval for Nine APIs
  - Peak Sales Expected to Exceed ¥10 Bil. for Five APIs
  - *Chuikyo* to Review Pricing Rule for Combination Drugs
  - Questions Raised Regarding High-Dose Versions of Cravit
- 12 Health Minister Opposed to ¥220 Bil. Cut in Social Security Spending
- 12 **REGULATORY NEWS IN BRIEF**
- 12 Prograf in Combination with MMF Approved in the US: Astellas

## TOPICS

- 12 Pfizer Japan Offers "No-Smoking Allowance" to Employees

## R&D

- 14 Eli Lilly Begins Two Global PIII Trials of Solanezumab
- 14 Tadalafil Improves PAH Patients' Exercise Capacity: Eli Lilly, United Therapeutics
- 15 Gov't to Consider Patent Rights on Treatment Regimens
- 14 **R&D NEWS IN BRIEF**
  - ANTCliPh Completes Three PK Studies
  - Acronet to Conduct PI Trial in Oncology in Kyushu
  - Medarex, Ono Announce Results of PI Studies on Fully Human Anti-PD-1 Antibody
  - Xarelto Reduces VTE Risk More Significantly than Enoxaparin
  - Gaster Prevents Peptic Ulcers in Users of Low-Dose Aspirin
  - Herceptin Prolongs Median Survival in Stomach Cancer: Roche
  - Mediscience, CPOC Tie Up

## Statistics

- 17 **Statistics**
  - Sales of Ethical Drugs Up 2.4% in FY2008 Compared to FY2007

## COMMENTARY

- 18 **Maurer's Healthcare Insight (109)**
  - Three Belly Cuts and Counting: P. Reed Maurer
- 19 **Survey**
  - RLS Takes Almost Four Years before Being Diagnosed

## MEDICAL FACILITIES & NURSING CARE

- 20 52nd JDS Annual Meeting
  - JDS to Issue New Diagnostic Criteria Based on HbA1C
  - DPP-4 Inhibitors Should Be Administered at Early Stage
  - Liraglutide More Effective than Exenatide for Decreasing HbA1c
  - Voglibose Saves Medical Expenses in People with IGT
  - Olmesartan Fails to Reach Primary Endpoint for Diabetic Nephropathy Patients
- 22 Larger-Scale, Dose-Finding PII Studies Necessary for Anticoagulants: Dr C.M. Gibson
  - Rivaroxaban Advances to PIII
- 23 New Antithrombotic Drugs That Solve Dilemma of Thrombotic Events and Hemorrhagic Events Needed: Prof. Goto